Vaxcyte PCVX 深 沪
已收盘 10-17 16:00:00 美东时间
42.39
-1.200
-2.75%
华盛通- 最 高43.91
- 今 开42.92
- 成交量 143.59万股
- 最 低 42.00
- 昨 收 43.59
- 总市值 55.11亿
- 52周最高 116.00
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 27.66
- 委 比 -79.96%
- 总股本 1.30亿
- 历史最高 121.055
- 量 比 0.62
- 振 幅 4.38%
- 历史最低 15.51
- 每 手 1
- 风险率 18.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ClearBridge SMID Cap Growth Strategy
The ClearBridge SMID Cap Growth Strategy underperformed its Russell 2500 Growth Index benchmark during the third quarter, with the index gaining 10.7%. As such, the performance of SMID growth equitie...
10-13 23:15
Thermo Fisher Scientific prices $2.5B senior notes
Thermo Fisher Scientific (NYSE:TMO) priced an offering of $2.5B senior notes consiting of: $500M 4.200% senior notes due 2031 at the issue price of 99.874%; $750M 4.473% senior notes due 2032 at the...
10-01 13:28
Vaxcyte Signs 15-Year Agreement with Patheon
An update from Vaxcyte ( ($PCVX) ) is now available. On September 24, 2025, Vax...
09-30 21:24
Vaxcyte Enters Partnership With Thermo Fisher Scientific To Secure Additional U.S. Fill-Finish Commercial Manufacturing For Its Broad-Spectrum Pneumococcal Conjugate Vaccines Representing Up To $1B in Manufacturing And Service
Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced a new agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to bring additional fill-finish
09-30 20:44
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
Vaxcyte has signed a deal with Thermo Fisher Scientific to expand its fill-finish commercial manufacturing capabilities in the U.S. for its broad-spectrum pneumococcal conjugate vaccines (PCVs). Thermo Fisher will provide custom manufacturing services at its Greenville, N.C., facility, supporting Vaxcyte's long-term U.S. supply strategy with up to $1 billion in capacity. The partnership aims to strengthen domestic biomanufacturing, enhance supply...
09-30 12:30
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
Goldman Sachs Initiates Coverage On Vaxcyte with Neutral Rating, Announces Price Target of $38
Goldman Sachs analyst Asad Haider initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Neutral rating and announces Price Target of $38.
09-12 23:32
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data
Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial.
09-11 22:23
Vaxcyte Advances Study of New Vaccine for Pneumococcal Disease in Infants, Pegtibatinase Maintained Significant Reductions in Toxic Metabolites
Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced advancement of the modified
09-03 19:33
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
Vaxcyte advances its VAX-31 infant Phase 2 study to evaluate the optimized dose of the 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease in infants. The optimized dose includes most serotypes at 4.4mcg and the balance at 3.3mcg, aiming to elicit stronger immune responses. The study, which now includes the optimized dose arm, will provide topline data by the end of the first half of 2027. VAX-31 i...
09-03 11:30
